Tecentriq®

Active substance

Atezolizumab

Holder

Roche

Status

Running

Indication

In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with stage IV or recurrent metastatic non-squamous non-small cell lung cancer (NSCLC) and whose tumors express PD-L1 < 50% with no EGFR or ALK positive tumors.

Public documents

Approbation

Information for the patient

Informed consent

Last update

26/02/2019